MedTrace Logo

Topiramate in the Treatment of Post Traumatic Stress Disorder (PTSD)

NCT00203463 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2009-07-29

No results posted yet for this study

Summary

To study the potential therapeutic effects of topiramate (Topamax) in the treatment of PTSD.

Conditions

Interventions

DRUG

topiramate

Sponsors & Collaborators

  • Ortho-McNeil Janssen Scientific Affairs, LLC

    collaborator INDUSTRY

  • Tuscaloosa Research & Education Advancement Corporation

    lead OTHER

Principal Investigators

  • Lori L Davis, MD · Tuscaloosa Veterans Affairs Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2001-07-31
Primary Completion
2004-09-30
Completion
2004-09-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00203463 on ClinicalTrials.gov